Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance pembrolizumab after definitive chemoradiotherapy for unresectable stage III non-small cell lung cancer
2024-514701-57-01Phase 2Authorised
- Sponsor
- University of Turin
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Turin. Primary endpoint: Median overall survival. Planned start Dec 2024; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-514701-57-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514701-57-01.